NYSEARCA:AIM - NYSE Arca - US00901B1052 - Common Stock - Currency: USD
0.1383
0 (-3.15%)
The current stock price of AIM is 0.1383 USD. In the past month the price decreased by -38.51%. In the past year, price decreased by -66.88%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. The company is headquartered in Ocala, Florida and currently employs 26 full-time employees. The company is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). Alferon N Injection is an injectable formulation of natural alpha interferon, which is approved for sale in the United States and Argentina for the intralesional treatment of refractory or recurring external genital warts in patients 18 years of age or older.
AIM IMMUNOTECH INC
2117 Sw Highway 484
Ocala FLORIDA 34473 US
CEO: Thomas K. Equels
Employees: 27
Company Website: https://aimimmuno.com/
Investor Relations: http://ir.hemispherx.net/
Phone: 13524487797
The current stock price of AIM is 0.1383 USD. The price decreased by -3.15% in the last trading session.
The exchange symbol of AIM IMMUNOTECH INC is AIM and it is listed on the NYSE Arca exchange.
AIM stock is listed on the NYSE Arca exchange.
6 analysts have analysed AIM and the average price target is 2.81 USD. This implies a price increase of 1928.2% is expected in the next year compared to the current price of 0.1383. Check the AIM IMMUNOTECH INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AIM IMMUNOTECH INC (AIM) has a market capitalization of 8.82M USD. This makes AIM a Nano Cap stock.
AIM IMMUNOTECH INC (AIM) currently has 27 employees.
AIM IMMUNOTECH INC (AIM) has a resistance level at 0.2. Check the full technical report for a detailed analysis of AIM support and resistance levels.
The Revenue of AIM IMMUNOTECH INC (AIM) is expected to decline by -7.64% in the next year. Check the estimates tab for more information on the AIM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AIM does not pay a dividend.
AIM IMMUNOTECH INC (AIM) will report earnings on 2025-03-31, after the market close.
AIM IMMUNOTECH INC (AIM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.48).
The outstanding short interest for AIM IMMUNOTECH INC (AIM) is 1.59% of its float. Check the ownership tab for more information on the AIM short interest.
ChartMill assigns a fundamental rating of 1 / 10 to AIM. Both the profitability and financial health of AIM have multiple concerns.
Over the last trailing twelve months AIM reported a non-GAAP Earnings per Share(EPS) of -0.48. The EPS decreased by -12.56% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -176.1% | ||
ROE | -821.74% | ||
Debt/Equity | 0.05 |
ChartMill assigns a Buy % Consensus number of 80% to AIM. The Buy consensus is the average rating of analysts ratings from 6 analysts.
For the next year, analysts expect an EPS growth of 41.93% and a revenue growth -7.64% for AIM